Randomized Phase 2 Study of Neoadjuvant Nivolumab with and without Urelumab in Cisplatin-Ineligible Patients with Muscle-Invasive Urothelial Carcinoma of the Bladder
Sponsor: |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR7552 |
U.S. Govt. ID: |
NCT02845323 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This research is being done to study the effects, safety, and tolerability of the study drugs Nivolumab and Urelumab when given to people with advanced bladder cancer that has spread into the muscle tissue, also called Muscle-Invasive Urothelial Carcinoma of the Bladder (MIBC). Specifically, this research study will have participants either take Nivolumab in combination with Urelumab or Nivolumab alone.
This study is closed
Investigator
Christopher Anderson, MD
Are you at least 18 years of age? |
Yes |
No |
Do you have muscle-invasive urothelial carcinoma of the bladder? |
Yes |
No |